Scarica l'app Stockscreener
1.07
0.93%
0.00
Precedente Chiudi:
$1.07
Aprire:
$1.0505
Volume 24 ore:
89,875
Relative Volume:
0.14
Capitalizzazione di mercato:
$43.14M
Reddito:
-
Utile/perdita netta:
$-66.88M
Rapporto P/E:
-0.5944
EPS:
-1.8
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+0.93%
1M Prestazione:
+8.87%
6M Prestazione:
+14.43%
1 anno Prestazione:
+34.16%
Intervallo 1D:
$1.05
$1.08
Intervallo di 1 settimana:
$1.01
$1.08
Portata 52W:
$0.63
$1.76
Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile
Nome
Achilles Therapeutics Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ACHL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ACHL | 1.07 | 43.14M | 0 | -66.88M | -62.91M | -1.80 |
| VRTX | 449.23 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.55 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 598.26 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.12 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-26 | Iniziato | JP Morgan | Underweight |
| 2021-04-26 | Iniziato | Oppenheimer | Outperform |
| 2021-04-26 | Iniziato | Piper Sandler | Overweight |
Achilles Therapeutics Plc Adr Borsa (ACHL) Ultime notizie
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market - GlobeNewswire Inc.
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why - Yahoo New Zealand News
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why - Yahoo Sport Australia
Achilles Therapeutics Plc ADR (ACHL) Clearly Signals Buy-Into the Stock: Don't ignore the signals – Sete News - SETE News
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study - Yahoo Lifestyle UK
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study - Yahoo Movies UK
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development - Yahoo Lifestyle UK
Achilles Therapeutics and Arcturus team up for cancer vaccine By Investing.com - Investing.com
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation ... - GlobeNewswire
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Achilles Therapeutics Plc ADR's Shares Reel: -0.12% Quarterly Revenue Decline Amid 37.75M Market Cap – Invest ... - The InvestChronicle
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC ... - GlobeNewswire
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference - GlobeNewswire
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation - Quantisnow
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why - Nasdaq
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity - Yahoo Finance Australia
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 - Yahoo New Zealand News
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board - GlobeNewswire
Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq
Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Achilles Therapeutics Plc Adr Azioni (ACHL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):